Antibody Drug Conjugates (ADC)
Posted: 19 February 2014 | | No comments yet
Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent answers the question: “Other than oncology, for which disease areas do you see Antibody Drug Conjugates (ADC) being used extensively in the future?”
Paul Wituschek, Catalent
“Other than oncology, for which disease areas do you see Antibody Drug Conjugates (ADC) being used extensively in the future?”
Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent:
The benefit of Antibody Drug Conjugates is their ability to provide highly targeted delivery of a therapeutic payload, which can significantly improve efficacy and reduce toxicity and side effects. Though much of the initial development of ADCs has focused on delivery of cytotoxic molecules to tumour cells, the technology can apply to any therapeutic indication where this targeted delivery will result in improved patient outcomes. As an example, small molecules that showed great efficacy in Phase III trials, but failed due to off target toxicity, may get a second look as an ADC. We see this potential in areas like autoimmune diseases, pain, diabetes, fibrotic diseases and many others. Developing products for these non-oncology indications can be enabled by technology platforms that allow various types of molecule conjugations (e.g. protein-therapeutic small molecule, protein-hormone, protein-peptide, protein-antibiotic or protein-RNA).